Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.

Patients with SDHD-associated head-and-neck paragangliomas (HNP) are at risk for developing pheochromocytomas for which screening has been advised. To assess clinical, biochemical, and radiological outcomes of screening in a large single-center cohort of SDHD-positive patients with HNP and to address the necessity for repetitive follow-up, we evaluated 93 patients with SDHD-associated HNP (p.Asp92Tyr, p.Leu139Pro). Screening consisted of measurement of 24 h urinary excretion of catecholamines and/or their metabolites in duplicate, which was repeated with intervals of 2 years if initial biochemical screening was negative. In patients, in whom urinary excretion was above the reference limit, imaging studies with (123)I-MIBG (metaiodobenzylguanidine) scintigraphy and magnetic resonance imaging (MRI) and/or computed tomography (CT) were performed. Pheochromocytomas and extra-adrenal paragangliomas were treated surgically after appropriate blockade. Median follow-up was 4.5 years (range 0.5-19.5 years). Twenty-eight out of the 93 patients were included in our study and underwent additional imaging for pheochromocytomas/extra-adrenal paragangliomas. In 11 out of the 28 patients intra-adrenal pheochromocytomas were found. Extra-adrenal paragangliomas were discovered in eight patients. These tumors were detected during initial screening in 63% of cases, whereas 37% were detected after repeated biochemical screening. One patient was diagnosed with a biochemically silent pheochromocytoma. The high prevalence of pheochromocytomas/extra-adrenal paragangliomas in patients with SDHD-associated HNP warrants regular screening for tumors in these patients. Paragangliomas that do not secrete catecholamines might be more prevalent than previously reported. Future studies will have to establish whether routine imaging studies should be included in the screening of SDHD mutation carriers, irrespective of biochemical screening.

[1]  M. Gurnell,et al.  The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. , 2007, European journal of endocrinology.

[2]  J. Carrasquillo,et al.  Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Romijn,et al.  Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  K. Pacak,et al.  Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[5]  A. Tischler,et al.  Pheochromocytoma: recommendations for clinical practice from the First International Symposium , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[6]  J. López-Barneo,et al.  Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  B. Robinson,et al.  Genetic basis of phaeochromocytoma and paraganglioma. , 2006, Best practice & research. Clinical endocrinology & metabolism.

[8]  M. Marzola,et al.  Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study , 2006, Nuclear medicine communications.

[9]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  D. Devendra,et al.  Increased urinary dopamine excretion in association with bilateral carotid body tumours - clinical, biochemical and genetic findings , 2006, Annals of clinical biochemistry.

[11]  D. Goldstein,et al.  Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. , 2005, The Journal of clinical endocrinology and metabolism.

[12]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[13]  J. Carrasquillo,et al.  Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  K. Pacak,et al.  Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  J. Schipper,et al.  18F-DOPA positron emission tomography for the detection of glomus tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  W. Young,et al.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  A. Vortmeyer,et al.  New Insights into the Genetics of Familial Chromaffin Cell Tumors , 2002, Annals of the New York Academy of Sciences.

[18]  M. Walther,et al.  Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.

[19]  H. Neumann,et al.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.

[20]  W. Young,et al.  Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. , 2001, The Journal of clinical endocrinology and metabolism.

[21]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[22]  P. Devilee,et al.  Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHD gene , 2001, Genes, chromosomes & cancer.

[23]  Graeme Eisenhofer,et al.  6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.

[24]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[25]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[26]  J. Lenders,et al.  Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[27]  M. Rehling,et al.  Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. , 1996, Clinical nuclear medicine.

[28]  P. Maaswinkel-Mooy,et al.  GENOMIC IMPRINTING IN HEREDITARY GLOMUS TUMOURS: EVIDENCE FOR NEW GENETIC THEORY , 1989, The Lancet.

[29]  P. Taschner,et al.  Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. , 2005, European journal of endocrinology.

[30]  H. Bonjer,et al.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. , 2001, The Journal of clinical endocrinology and metabolism.

[31]  M. Volmer,et al.  Evaluation of urinary metanephrine and normetanephrine enzyme immunoassay (ELISA) kits by comparison with isotope dilution mass spectrometry. , 1997, Clinical chemistry.

[32]  M. Monk.  Genomic imprinting. , 1988, Genes & development.